KNSA Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference

Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference

HAMILTON, Bermuda, June 01, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) announced today that it will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 9:40 a.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at . A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference.

About Kiniksa

Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio of assets, ARCALYST® (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit .

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts!™

Kiniksa Investor and Media Contact

Rachel Frank

(339) 970-9437



EN
01/06/2021

Underlying

KNSAKiniksa Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports by Kiniksa Pharmaceuticals

 PRESS RELEASE
Free
KNSA Kiniksa Pharmac... (Health Care)

Kiniksa Announces Launch of ARCALYST Named Patient Program

Kiniksa Announces Launch of ARCALYST Named Patient Program - Named Patient Program supports patient access to ARCALYST® (rilonacept) in countries where ARCALYST is not currently commercially available - HAMILTON, Bermuda, Aug. 16, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced the launch of a Named Patient Program for ARCALYST, a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1 alpha (IL-1α) and int...

August 16, 2021 1 EN
David Nierengarten
  • David Nierengarten
KNSA KINIKSA PHARMACEUTICALS (Health Care)
08/03/21 August 3, 2021 6 EN
 PRESS RELEASE
Free
KNSA Kiniksa Pharmac... (Health Care)

Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corpo...

Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity - Q2 2021 ARCALYST® (rilonacept) net revenue of $7.7 million with greater than 100 prescribing physicians - - Phase 3 data from mavrilimumab clinical trial in COVID-19-related ARDS on-track for Q1 2022; new Phase 2 data demonstrate persistent clinical effect through Day 90 - - Initiation of KPL-404 Phase 2 proof-of-concept clinical trial expected in Q4 2021 - - Conference call and webcast scheduled for 8:30 a.m. ET today - HAMILTON, Bermuda, Aug. 03, 2021 (GLOBE NEWSWIRE) --   (Nasdaq: KN...

August 3, 2021 1 EN
 PRESS RELEASE
Free
KNSA Kiniksa Pharmac... (Health Care)

Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Result...

Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021 HAMILTON, Bermuda, July 20, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, August 3, 2021 at 8:30 a.m. Eastern Time to report its second quarter 2021 financial results and recent corporate and portfolio activity. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will be available on Kiniksa’s website for 14 ...

July 20, 2021 1 EN
David Nierengarten
  • David Nierengarten
KNSA KINIKSA PHARMACEUTICALS (Health Care)
06/08/21 June 8, 2021 5 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch